Affluent Medical to Merge with Caranx Medical and Artedrone, Forming Carvolix to Advance AI-Driven Robotic Platforms in Valvular and Neurovascular Interventions

Affluent Medical Announces Partnership with Caranx MedicalAffluent Medical and Artedrone have reached an acquisition agreement,Affluent Medical will acquire Caranx Medical for approximately $19.5 million (€16.6 million) and Artedrone for approximately $13.4 million (€11.4 million).

Affluent MedicalThrough this strategic integration, a new enterprise will be created to meet the needs of modern cardiovascular diagnosis and treatment ---Carvolix。CarvolixWill IntegrateCombining AI-driven autonomous micro-robotics technology, aimed at making complex life-saving surgeries more accessible.

Executive Evaluation

"We are applying a proven business model — integrating the technical capabilities of Truffle's portfolio companies to reduce R&D risks, accelerate innovation, and unlock shareholder value. Our goal is to make cardiac catheterization labs as autonomous and efficient as an airplane cockpit, bringing breakthrough innovations to millions of patients worldwide."

---Philippe Pouletty  CEO of Truffle Capital and Founder of Affluent Medical

"We are merging three highly innovative and synergistic medical technology companies to upgrade cardiac catheterization labs and provide treatment for more patients with valvular dysfunction and stroke. Additionally, we will enhance the synergy among the three companies in R&D and commercialization to drive the development and delivery of other products, such as robotic mitral valve delivery."

---Sebastien Ladet  CEO of Affluent Medical and Incoming CEO of Caranx Medical

"We are building an excellent management team and board of directors to fulfill the corporate mission – to become a leader in the commercial-stage medical technology sector, fully supporting interventional cardiologists in providing treatment to more patients worldwide."

---Liane Teplitsky  CEO of Artedrone and Incoming Executive Chairman of Carvolix

Affluent Medical、CaranAffluent Medical and Artedrone both originate fromTruffle Capital。Truffle Capital hopes that this integration will stimulate the potential of the three companies, therebyBuilding a company that serves 21st-century interventional cardiology experts — leveraging globally leading AI-driven autonomous micro-robotics technology to promote the democratization of complex life-saving surgeries.

After integration, the new company Carvolix will focus on revolutionary breakthroughs in heart valve replacement and stroke treatment, addressing significant unmet medical needs in a massive market valued at 23 billion euros. Currently, only 17% of the 1.7 million patients suitable for transcatheter aortic valve implantation (TAVI) actually undergo the procedure each year; only 5% of ischemic stroke patients (the second leading cause of death globally and the third leading cause of disability) receive mechanical thrombectomy. Similarly, only 4% of four million patients with severe mitral regurgitation undergo surgical treatment.

CarvolixThe deep expertise and R&D synergies in micro-robotics, artificial intelligence, image-guided navigation, catheter, and valve technologies will accelerate the innovation process and establish a robust and continuous product development rhythm.

Carvolix

• Affluent Medical

 Affluent MedicalDedicated to providing the world's best available therapies to address unmet needs in widespread and significant diseases so far. Millions of patients around the world are suffering and consistently unable to find the optimal treatment.

• Caranx Medical

Caranx MedicalIs an innovative medical technology company,Aiming to become the global leader in robot-assisted transcatheter heart valve implantation.WillThe integration of imaging, artificial intelligence, and robotics has transformed cardiovascular interventional procedures into an autopilot mode, making valve surgeries simpler, more reliable, and safer, while allowing both patients and doctors to benefit.

The world's first AI software for guiding TAVI procedures during surgeryTavipilot Software has been approved by the FDA for commercial use and completed its first commercial application.

• Artedrone

ArtedroneFounded in 2017 (by Truffle Capital), Artedrone is committed to revolutionizing the field of interventional neuroradiology by providing autonomous robotic solutions for stroke treatment.The goal is to enable more medical centers to implement mechanical thrombectomy, thereby expanding the accessibility of this therapy.